Hutchmed

This Phase 3 trial tested an oral drug called HMPL-523 (sovleplenib) in 272 adults with chronic immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants who had not responded well to prior treatments received eith…

This study tested a daily pill called surufatinib in 36 Japanese patients with neuroendocrine tumors that had stopped responding to other treatments. The goal was to see if the drug is safe and whether it can shrink tumors. The trial combined an early safety phase with a later ph…

This study investigates how two common drugs—itraconazole (a CYP3A and P-gp inhibitor) and rifampin (a CYP enzyme inducer)—affect the levels of HMPL-453 in the blood of healthy adults. Forty participants will take HMPL-453 alone and then with each of these drugs to see how they c…

This completed Phase 1 study gave 6 healthy Chinese men a single oral dose of a radiolabeled drug called HMPL-453 to see how it is absorbed, broken down, and eliminated. Researchers measured radioactivity in blood, urine, and feces over time. The goal was not to treat any disease…

This early-stage study looked at how eating a high-fat or low-fat breakfast changes the way the body absorbs a new drug called HMPL-523. Eighteen healthy Chinese adults took a single 300 mg tablet under different meal conditions. The goal was to see if food affects drug levels in…

This completed Phase 1 study enrolled 54 healthy Chinese adults to compare two different tablet formulations of the experimental drug HMPL-523. Participants received a single 300 mg dose of each version in random order, and researchers measured drug levels in the blood to see if …